Relmada Therapeutics (RLMD) Finished Goods (2012 - 2013)

Relmada Therapeutics' (RLMD) quarterly Finished Goods came in at $4734.0 in Q4 2013, up 49.38% on a QoQ basis from $3169.0 in Q3 2013.

Relmada Therapeutics (RLMD) Finished Goods (2012 - 2013) Analysis & Trends

Relmada Therapeutics (RLMD) has 2 years of Finished Goods data on file, last reported at $4734.0 in Q4 2013.

On a quarterly basis, Finished Goods changed N/A year-over-year to $4734.0 in Q4 2013; TTM through Nov 2013 was $4734.0, a N/A change from a year earlier, with the FY2013 full-year figure at $3169.0, down 50.52% from the prior year.
Finished Goods for Q4 2013 stood at $4734.0, up from $3169.0 in the prior quarter.
Over the last five years, Finished Goods for RLMD reached as high as $6405.0 in Q3 2012 and fell as low as $2369.0 in Q2 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Relmada Therapeutics	205.29 Mn	205.29 Mn	-

Download Data